Open access

Longitudinal plasma phosphorylated tau217 classification and the association with Alzheimer's disease progression

Guo-Yu Lan Wang Liao Mingxing Jiang Jiayi Zhu Wen-Qing Ran F. González-Ortiz Xiang Fan Hong-Jie Yang Dai Shi Laihong Zhang Anqi Li Yue Cai Pan Sun Zheng-Bo He Xin Zhou Jie Yang Yalin Zhu Mingxu Li Wen-Jing Huang Bin-Hui Liu Yi-Ying Wang Xinyue Ma Rong Ma Yi-Mei Zhang Chao Huang Zhen Liu Qing-Yong Wang Lie-Min Zhou Fang Xie Ying Han Zhen Liang Xu-Hui Chen Meng-Jie Dong Guan-Xun Cheng Lu Wang Ben-Yan Luo Yan-Jiang Wang Xiao-Chun Chen Jiawei Xin Guo-Ping Peng Teng-Fei Guo

Aug 2026 · Alzheimer's & Dementia · Vol 22 · 0 citations · 41 references

Medicine

Abstract

Longitudinal diagnostic and prognostic validity of plasma phosphorylated tau217 (p‐tau217) in Alzheimer's disease (AD) remains uncertain.

DOI PubMed Semantic Scholar

Read PDF

Similar papers

Open access Jul 2026

Heterogeneity in plasma p‐tau217 response and its association with cognitive trajectories under lecanemab treatment

Plasma phosphorylated tau 217 (p‐tau217) is a promising biomarker for monitoring treatment response in Alzheimer's disease (AD), but its longitudinal dynamics and clinical relevance remain unclear.

Sung-Hoon Kang, Yu Jeong Park, Seung-Yun Lee et al. · Alzheimer's & Dementia · 0 citations

Open access Aug 2026

Elucidating the neuropathological and molecular heterogeneity of amyloid beta and tau in Alzheimer's disease through machine learning and transcriptomic integration

Functional brain network alterations associated with Alzheimer's disease (AD) pathology, including amyloid beta (Aβ) and phosphorylated tau (p‐tau), are difficult to interpret due to overlapping aging‐associated and non‐amyloid biological processes.

K. Zhao, Hua Xie, Tovia Jacobs et al. · Alzheimer's & Dementia · 0 citations

Open access Jul 2026

Exploring longitudinal relationships among Alzheimer's disease biomarkers

While most studies of Alzheimer's disease (AD) examine cross‐sectional relationships among biomarkers, longitudinal relationships are also highly relevant.

B. Saef, K. K. Petersen, Katherine E. Volluz et al. · Alzheimer's & Dementia · 0 citations

Open access Sep 2026

Digital cognitive phenotyping enhances risk stratification in preclinical Alzheimer's disease

Amyloid positivity does not reliably predict near‐term cognitive decline in preclinical Alzheimer's disease (AD). We tested whether digital cognitive phenotyping improves prognostic precision.

C. Vanderlip, Craig E. L. Stark · Alzheimer's & Dementia · 0 citations

Open access Sep 2026

Baseline cerebrospinal fluid complement balance is associated with longitudinal memory decline in relation to plasma p‑tau181 levels in mild cognitive impairment

The role of complement in Alzheimer's disease (AD) remains unclear, particularly regarding tau pathology and memory decline.

Zhi-Nan Ye, Qi-Han Zhang, Bo Zhang et al. · Alzheimer's & Dementia · 0 citations

Open access Sep 2026

Enhancing early Alzheimer's disease clinical trials through prognostic score covariate adjustment

A prognostic score (PS) summarizes a patient's expected disease progression and can increase the statistical efficiency of clinical trials when included as an analysis covariate.

B. T. Scodari, Roland Brown, Xiao-Tong Jiang et al. · Alzheimer's & Dementia · 0 citations